Additional Approval of SGLT2 inhibitor CANAGLU® OD Tablets～First OD Tablets of SGLT2 inhibitors in Japan～

1/1 March 18, 2024 Additional Approval of SGLT2 inhibitor CANAGLU® OD Tablets ~ First OD Tablets of SGLT2 inhibitors in Japan ~ Mitsubishi Tanabe Pharma Corporation (Head Office: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of the Mitsubishi Chemical Group, obtained approval for an additional dosage form of orally disintegrating (OD) tablets for SGLT2 inhibitor CANAGLU® T ablets 100 mg (generic name: Canagliflozin Hydrate, hereinafter, “CANAGLU® Tablets”) on March 15. CANAGLU® OD T ablet is the first SGLT2 inhibitor OD tablet approved in Japan. Since it disintegrates easily in a small amount of water, it dissolves quickly with water such as saliva in the mouth and is easy to swallow and can be taken without or with water without depending on the place. It is expected to improve convenience and to continue taking the drug for people with type 2 diabetes who need continuous treatment. MTPC has been selling OD tablets of a selective DPP-4 inhibitor TENELIA® T ablets (generic name: T eneligliptin Hydrobromide Hydrate) since June 2021. TENELIA® OD tablets are the only OD tablets of a selective DPP-4 inhibitor in Japan at present. In addition, an application for an additional dosage form of OD tablets for CANALIA® Combination T ablets, which are combination drugs of TENELIA® T ablets and CANAGLU® Tablets, was submitted in February 2024. MTPC will continue working to deliver the new treatment options for people living with type 2 diabetes to enhance satisfaction with treatment and convenience. Contact: Mitsubishi Chemical Group Corporation Corporate Communications Division Osaka Corporate Communications Department +81-6-6205-5119

The release as fetched from its publisher. tanabe-pharma.com ↗